BEIGENE (06160) announced its financial results for 2025. In the fourth quarter of 2025, total global revenue reached $1.5 billion, representing a 33% increase year-over-year. For the full year 2025, total global revenue amounted to $5.3 billion, a 40% increase compared to the previous year.
The company reported an adjusted net profit of approximately $225 million for the fourth quarter, a significant increase of 12.97 times compared to the same period last year. For the full year, the adjusted net profit was approximately $918 million, marking a turnaround from a loss in the prior year.
In the fourth quarter, free cash flow was $380 million, an increase of $397 million compared to the same quarter in 2024. For the full year 2025, free cash flow reached $942 million, an increase of $1.6 billion year-over-year.
The company provided revenue guidance for the full year 2026, projecting total revenue to be between $6.2 billion and $6.4 billion.
Sales of BRUKINSA® (zanubrutinib) reached $1.1 billion globally in the fourth quarter, a 38% increase year-over-year. Its annual global sales for 2025 totaled $3.9 billion, growing 49% compared to 2024.
Global sales of TEVIMBRA® (tislelizumab) were $182 million in the fourth quarter, an 18% increase year-over-year. Full-year global sales for TEVIMBRA® reached $737 million, a 19% increase.
"The strong financial performance in the fourth quarter and full year 2025 demonstrates our continued evolution into a leader in global oncology," said John V. Oyler, Co-founder, Chairman, and Chief Executive Officer of BEIGENE. "This achievement is built upon the durable competitive advantages we have established in clinical development and manufacturing, as well as one of the deepest and most differentiated pipelines in the industry."
"BRUKINSA® has firmly established its position as a global leader in the BTK inhibitor class. Its broad regulatory approvals, expanding global footprint, high recognition from clinicians, and unparalleled long-term efficacy and safety data in chronic lymphocytic leukemia (CLL) collectively create a significant leading advantage. Simultaneously, we are continuing to expand the indications and reimbursement coverage for TEVIMBRA® in major global markets. With several cornerstone hematology assets in late-stage clinical development nearing commercialization and a robust solid tumor pipeline continuing to generate encouraging data, we are well-positioned to further extend our leadership and advance towards the next phase of sustainable global growth."
Comments